{"id":"W3165419638","doi":"10.1136/annrheumdis-2021-eular.1971","title":"POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Novartis Pharma; Celgene; Novartis Pharmaceuticals Corporation; Pfizer; Eli Lilly and Company","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Placebo; Internal medicine; Quality of life (healthcare); Physical therapy; Clinical trial; Disease; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009864677,0.001319841,0.00189473,0.000310313,0.0004074393,0.0007942928,0.0004937965,0.0008720152,0.0035179],"category_scores_gemma":[0.0005138958,0.0003417517,0.001848034,0.0003301131,0.0006578847,0.0005806061,0.0002202655,0.002394543,0.0008540627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004029928,"about_ca_system_score_gemma":0.0004822803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006076255,"about_ca_topic_score_gemma":0.001633894,"domain_scores_codex":[0.9996982,0.000115863,0.00002131667,0.00004481837,0.00004130311,0.00007853712],"domain_scores_gemma":[0.9996352,0.00008634092,0.00007819825,0.00003354571,0.00002606769,0.0001405833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6574013,0.05049055,0.01309836,0.001421285,0.004447745,0.0004457701,0.0002824228,0.002096713,0.05199422,0.0001936988,0.003754183,0.2143737],"study_design_scores_gemma":[0.3036955,0.6214164,0.06541245,0.00008375766,0.001511077,0.0005173348,0.0001311177,0.001071059,0.003702532,0.000161859,0.00223775,0.00005919877],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995554,0.002432704,0.0001767129,0.0002102917,0.00009180047,0.0002601151,0.0003092607,0.00007337555,0.0008916277],"genre_scores_gemma":[0.9954379,0.001382841,0.0003677855,0.0005820683,0.0001064668,0.0002251904,0.0008163737,0.00001618691,0.001065246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0035179,"threshold_uncertainty_score":0.01176852,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01723638826665016,"score_gpt":0.3099679467104146,"score_spread":0.2927315584437644,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}